VIR vs. SWTX, RARE, AKRO, ALVO, IMVT, VKTX, RYTM, SRRK, CRNX, and MRUS
Should you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), Alvotech (ALVO), Immunovant (IMVT), Viking Therapeutics (VKTX), Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), Crinetics Pharmaceuticals (CRNX), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry.
Vir Biotechnology vs.
SpringWorks Therapeutics (NASDAQ:SWTX) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, community ranking, risk, media sentiment, profitability and institutional ownership.
SpringWorks Therapeutics presently has a consensus price target of $73.20, suggesting a potential upside of 54.36%. Vir Biotechnology has a consensus price target of $35.67, suggesting a potential upside of 433.53%. Given Vir Biotechnology's higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than SpringWorks Therapeutics.
SpringWorks Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.
SpringWorks Therapeutics has higher revenue and earnings than Vir Biotechnology. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
SpringWorks Therapeutics received 50 more outperform votes than Vir Biotechnology when rated by MarketBeat users. Likewise, 71.62% of users gave SpringWorks Therapeutics an outperform vote while only 56.00% of users gave Vir Biotechnology an outperform vote.
SpringWorks Therapeutics has a net margin of -134.73% compared to Vir Biotechnology's net margin of -678.40%. Vir Biotechnology's return on equity of -36.71% beat SpringWorks Therapeutics' return on equity.
65.3% of Vir Biotechnology shares are held by institutional investors. 7.6% of SpringWorks Therapeutics shares are held by insiders. Comparatively, 15.6% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, SpringWorks Therapeutics had 3 more articles in the media than Vir Biotechnology. MarketBeat recorded 7 mentions for SpringWorks Therapeutics and 4 mentions for Vir Biotechnology. SpringWorks Therapeutics' average media sentiment score of 1.38 beat Vir Biotechnology's score of 0.82 indicating that SpringWorks Therapeutics is being referred to more favorably in the media.
Summary
SpringWorks Therapeutics beats Vir Biotechnology on 10 of the 17 factors compared between the two stocks.
Get Vir Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vir Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:VIR) was last updated on 3/28/2025 by MarketBeat.com Staff
